We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+28.55%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$465M
AUM Growth
+$35.8M
Cap. Flow
-$14.7M
Cap. Flow %
-3.15%
Top 10 Hldgs %
71.37%
Holding
58
New
2
Increased
2
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
PRME icon
Prime Medicine
PRME
+$8.5M
2
IMTX icon
Immatics
IMTX
+$5.12M
3
ZYME icon
Zymeworks
ZYME
+$4.57M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$4.4M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$21.3M
2
JYAC
Jiya Acquisition Corp. Class A Common Stock
JYAC
+$5.05M
3
VRNA
Verona Pharma
VRNA
+$3.25M
4
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$3.01M
5
ACLX
Arcellx
ACLX
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$135M 29.11%
5,161,888
– –
SRRK icon
2
Scholar Rock
SRRK
$5.71B
$41.6M 8.96%
4,598,828
– –
ACLX
3
DELISTED
Arcellx
ACLX
$29.7M 6.38%
957,451
-106,384
-10% -$2.44M
LENZ
4
LENZ Therapeutics
LENZ
$172M
$28.1M 6.04%
1,208,473
– –
VRNA
5
DELISTED
Verona Pharma
VRNA
$18.2M 3.91%
695,001
-243,889
-26% -$3.25M
RAIN
6
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$18.1M 3.89%
2,260,652
+700,000
+45% +$4.4M
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.3M 3.72%
808,041
– –
NKTX icon
8
Nkarta
NKTX
$162M
$17.2M 3.7%
2,868,035
– –
STRO icon
9
Sutro Biopharma
STRO
$379M
$13.5M 2.91%
167,558
– –
ZYME icon
10
Zymeworks
ZYME
$1.68B
$12.7M 2.74%
1,620,687
+649,700
+67% +$4.57M
ACRS icon
11
Aclaris Therapeutics
ACRS
$730M
$11M 2.36%
696,171
– –
HLVX
12
DELISTED
HilleVax
HLVX
$10.2M 2.2%
610,062
– –
RYTM icon
13
Rhythm Pharmaceuticals
RYTM
$7B
$10.1M 2.16%
345,293
– –
PRME icon
14
Prime Medicine
PRME
$533M
$8.74M 1.88%
+470,304
New +$8.5M
PEPG icon
15
PepGen
PEPG
$133M
$8.7M 1.87%
651,050
– –
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$7.93M 1.71%
640,688
– –
DICE
17
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$6.33M 1.36%
202,773
-50,693
-20% -$1.65M
LYRA
18
DELISTED
LYRA THERAPEUTICS INC
LYRA
$5.58M 1.2%
35,545
– –
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
$5.25M 1.13%
1,693,736
– –
JANX icon
20
Janux Therapeutics
JANX
$935M
$4.75M 1.02%
360,414
– –
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
$4.72M 1.02%
659,409
– –
IMCR icon
22
Immunocore
IMCR
$1.78B
$4.62M 0.99%
80,963
– –
TNGX icon
23
Tango Therapeutics
TNGX
$4.34B
$4.57M 0.98%
630,000
– –
IMTX icon
24
Immatics
IMTX
$1.24B
$4.31M 0.93%
+495,000
New +$5.12M
DAWN
25
DELISTED
Day One Biopharmaceuticals
DAWN
$4.23M 0.91%
196,425
– –
1
2 3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q4 2022 Portfolio in Review

As of Q4 2022, Samsara BioCapital held 58 positions worth $465M, up 8.3% from $429M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Samsara BioCapital withdrew a net $14.7M in Q4 2022, closing 3 positions and reducing 4 holdings. Its most notable exit was Forma Therapeutics Holdings, Inc. Common Stock, an estimated $21.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in Prime Medicine worth $8.74M.

  • Samsara BioCapital's largest Q4 2022 buy was Prime Medicine: 470,304 shares worth $8.74M.
  • Samsara BioCapital added most to Zymeworks in Q4 2022, an estimated $4.57M increase.
  • Samsara BioCapital's biggest Q4 2022 reduction was Verona Pharma, cutting an estimated $3.25M.
  • Samsara BioCapital fully exited Forma Therapeutics Holdings, Inc. Common Stock in Q4 2022, selling an estimated $21.3M.
  • Samsara BioCapital's ten largest holdings make up 71% of its $465M portfolio in Q4 2022.
  • Samsara BioCapital opened 2 new positions and closed 3 in Q4 2022.
  • Samsara BioCapital's portfolio value rose 8.3% quarter-over-quarter to $465M.

Based on Samsara BioCapital's 13F filing for Q4 2022, filed 14 Feb 2023.